Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177 Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand
Asia-Pacific Journal of Clinical Oncology · 2025
DOI: 10.1111/ajco.14187 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Onnicha Pattanawong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Master of Science Program in Medical Physics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radioisotopes, Radiopharmaceuticals. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
177 Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177 Lu‐PSMA‐RLT from two university‐based hospitals in Thailand.
Methods
We retrospectively analyzed 61 treatment cycles in 36 patients who underwent posttreatment whole‐body planar imaging at three time points (1, 24, and 168 h postadministration). Absorbed doses were computed using organ based MIRD (Medical Internal Radiation Dosimetry) method with OLINDA/EXM v.2.2 in Hermes dosimetry software.
Results
The median treated activity was 5.79 GBq (range 5.00–7.29 GBq). Normal organ absorbed doses, from lowest to highest, were red marrow (0.03 ± 0.03 Gy/GBq), total body (0.04 ± 0.03 Gy/GBq), liver (0.13 ± 0.33 Gy/GBq), salivary glands (0.65 ± 0.42 Gy/GBq), and kidneys (0.72 ± 0.36 Gy/GBq).
Conclusion
Absorbed doses to normal organs remained within an acceptable range and not exceed the tolerance limits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Master of Science Program in Medical Physics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Krisanat Chuamsaamarkkee
Zitieren
APA
Pattanawong, O., Charoenphun, P., Chamroonrat, W., Thongpraparn, T., Poon-Iad, N., Khiewvan, B., & Chuamsaamarkkee, K. (2025). Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177 Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14187
Vancouver
Pattanawong O, Charoenphun P, Chamroonrat W, Thongpraparn T, Poon-Iad N, Khiewvan B, et al. Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177 Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.14187
BibTeX
@article{Pattanawong2025,
author = {Pattanawong, Onnicha and Charoenphun, Putthiporn and Chamroonrat, Wichana and Thongpraparn, Thonnapong and Poon-Iad, Nucharee and Khiewvan, Benjapa and Chuamsaamarkkee, Krisanat},
title = {Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177 Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2025},
doi = {10.1111/ajco.14187}
}
EUVIMED